- $725.99m
- $674.90m
- $183.88m
Brief: Geron Corp Says Co Entered Into At Market Issuance Sales Agreement With B. Riley Securities
Brief: Geron Q3 EPS USD -0.08
Geron Corp expected to post a loss of 10 cents a share - Earnings Preview
Brief: Geron Announces EMA Validation Of Marketing Authorization Application For Imetelstat For The Treatment Of Lower Risk Mds
Refinitiv Newscasts - Trump found liable for fraud in New York civil case
GS ups Morphosys to 'neutral' ahead of MANIFEST-2 trial readout
Brief: Geron Announces Appointment Of Michelle Robertson As Executive Vice President, Chief Financial Officer And Treasurer
Brief: Geron Corp says FDA Has Assigned Review And PDUFA Action Date Of June 16, 2024 To NDA Of Imetelstat
Brief: Geron FDA Assigned PDUFA Action Date For NDA For Imetelstat In Lower Risk Mds
U.S. STOCKS ON THE MOVE-Natgas firms, Moderna, VinFast
U.S. STOCKS ON THE MOVE-Energy firms, copper miners, natgas firms
U.S. STOCKS ON THE MOVE-Earthstone Energy, Dupont, Geron
Geron up after FDA accepts marketing application for blood disorder drug
Brief: Geron says FDA Accepts Of New Drug Application For The Treatment Of Lower Risk Mds
Geron Corp reports results for the quarter ended in June - Earnings Summary
Brief: Geron Q2 EPS USD -0.09
Geron Corp expected to post a loss of 8 cents a share - Earnings Preview
Brief: Geron Corp Expanded Access Protocol Is Available For Imetelstat, Co's First-In-Class Telomerase Inhibitor
Brief: Geron Corp Expects To Submit A Marketing Authorization Application In EU In Second Half Of 2023